Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dendrite initiation and deflection in biaxially stressed solid electrolytes.

Nature·2026
Same author

A Gender-Based Descriptive Analysis of the Canadian Network Undertaking Against Hepatitis C (CANUHC) Cohort From 2015-2023.

Open forum infectious diseases·2026
Same author

Impact of gastrectomy on the risk of alcohol-associated liver disease in patients with gastric cancer.

Scientific reports·2026
Same author

Heterogeneous doping via nanoscale coating impacts the mechanics of Li intrusion in brittle solid electrolytes.

Nature materials·2026
Same author

Prevalence of cirrhotic cardiomyopathy in liver transplant candidates: Impact on pre- and post-transplant mortality.

Annals of hepatology·2025
Same author

Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition.

Hepatobiliary surgery and nutrition·2025

Related Experiment Video

Updated: Jul 3, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Amiodarone hepatotoxicity.

Mohamed Babatin1, Samuel S Lee, P Timothy Pollak

  • 1Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Current Vascular Pharmacology
|August 5, 2008
PubMed
Summary
This summary is machine-generated.

Amiodarone can cause liver damage (hepatotoxicity) at any time during treatment or even after stopping the drug. Monitoring liver function is crucial for patients receiving amiodarone therapy.

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Experiment Videos

Last Updated: Jul 3, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Area of Science:

  • Pharmacology
  • Hepatology
  • Clinical Medicine

Background:

  • Amiodarone is a widely used antiarrhythmic drug.
  • Hepatotoxicity is a known potential adverse effect of amiodarone therapy.
  • Current understanding of amiodarone-induced liver injury and optimal monitoring strategies is limited.

Purpose of the Study:

  • To review the existing literature on amiodarone-associated liver effects.
  • To examine the incidence, pathogenesis, and mechanisms of amiodarone hepatotoxicity.
  • To provide clinical recommendations for monitoring liver function in patients on amiodarone.

Main Methods:

  • Literature review of studies on amiodarone and liver effects.
  • Emphasis on clinical data and expert consensus.
  • Analysis of incidence, risk factors, and monitoring guidelines.

Main Results:

  • Amiodarone-induced hepatotoxicity can occur at any point during therapy, including early intravenous use and after discontinuation.
  • Most cases are asymptomatic and detected incidentally via liver biochemistry tests.
  • Severe symptomatic liver injury or failure is rare.

Conclusions:

  • Hepatotoxicity is a significant concern with amiodarone, requiring careful consideration.
  • Optimal monitoring protocols for amiodarone-treated patients are not well-established.
  • Further prospective studies are needed to clarify incidence and guide monitoring practices.